High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome

(2009) K. I. Mills et al.   BLOOD

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

(2008) C. Langer et al.   BLOOD

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

(2008) T. Burmeister et al.   BLOOD

Optimal management of adults with ALL

(2008) Jacob M. Rowe   BRITISH JOURNAL OF HAEMATOLOGY

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Adult Acute Lymphoblastic Leukemia

(2008) Nicola Gökbuget et al.   SEMINARS IN HEMATOLOGY

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

(2007) N. Kawamata et al.   BLOOD